Table 2.
Univariate analysis of relevant prognostic factors for 2 year Progression-free Survival.
| Survival Estimate | Log Rank Test | ||||
|---|---|---|---|---|---|
| Factor | Strata | Total N | Estimate | CI 95% | P-value |
| Age (years) | 18-20 | 11 | 55% | 23- 78% | 0.48 |
| 20, 30 | 27 | 42% | 23- 60% | ||
| 30, 40 | 25 | 59% | 38- 76% | ||
| 40, 50 | 12 | 67% | 34- 86% | ||
| 50, 60 | 14 | 55% | 26- 77% | ||
| 60,70 | 6 | 33% | 5- 68% | ||
| Prior XRT | YES | 34 | 59% | 40- 73% | 0.61 |
| NO | 62 | 50% | 37- 62% | ||
| Stage | I/II | 37 | 61% | 43- 75% | 0.21 |
| III/IV | 59 | 49% | 35- 61% | ||
| B symptoms | YES | 52 | 42% | 28- 55% | 0.01 |
| NO | 44 | 67% | 51- 79% | ||
| Extra-nodal disease | YES | 31 | 45% | 27- 61% | 0.08 |
| NO | 65 | 57% | 44- 68% | ||
| Bone Marrow ds | YES | 11 | 55% | 23- 78% | 0.88 |
| NO | 85 | 53% | 42- 63% | ||
| Response to salvage therapy | CR | 56 | 62% | 48- 73% | 0.03 |
| PIF sensitive | 16 | 30% | 10- 53% | ||
| PR | 24 | 49% | 27- 67% | ||
| Histology | NS | 83 | 51% | 39- 61% | 0.53 |
| MC | 6 | 67% | 19- 90% | ||
| Other | 7 | 71% | 26- 92% | ||
| LDH@ AHCT | < ULN | 85 | 52% | 41- 62% | 0.78 |
| > ULN | 7 | 57% | 17- 84% | ||
| Albumin @ AHCT | <= 3.5g/dl | 86 | 52% | 41- 63% | 0.76 |
| > 3.5g/dl | 6 | 50% | 11- 80% | ||
| Hemoglobin @AHCT | < 10g/dl | 69 | 49% | 37- 61% | 0.57 |
| >= 10g/dl | 23 | 61% | 38- 77% | ||
| ALC @AHCT | < 1×10^3/ml | 42 | 49% | 32- 64% | 0.77 |
| >= 1×10^3/ml | 50 | 54% | 39- 67% | ||
| CD34 count/µL | <4.985 | 47 | 57% | 42- 70% | 0.52 |
| >=4.985 | 47 | 52% | 37- 66% | ||
| Plerixafor | YES | 14 | 29% | 8- 56% | 0.30 |
| NO | 79 | 57% | 45- 67% | ||
| Chemotherapy regimen | <3 | 71 | 56% | 43- 66% | 0.43 |
| ≥3 | 25 | 48% | 28- 66% | ||
| Graft source | Marrow | 1 | 0% | 0.62 | |
| PBSC | 85 | 53% | 42- 63% | ||
| Marrow+PBSC | 10 | 58% | 23- 82% | ||
| Duration of 1st remission | ≥1yr | 78 | 58% | 46- 68% | 0.02 |
| <1yr | 18 | 33% | 14- 55% | ||